

1 **Appendix A: Comprehensive Author Relationships With Industry and other entities—**
 2 **ACC/AHA/AACVPR/AAFP/ANA The Concepts for Clinician–Patient Shared Accountability in**
 3 **Performance Measures**

Name	Employment	Consultant	Speaker	Ownership/ Partnership/ Principal	Research	Institutional, Organizational, or Other Financial Benefit	Expert Witness
Eric. D. Peterson, Chair	Executive Director, Duke Clinical Research Institute	<ul style="list-style-type: none"> • Boehringer Ingelheim • Genentech • Janssen Pharmaceuticals • Johnson & Johnson • Merck 	None	None	<ul style="list-style-type: none"> • Eli Lilly† • Johnson & Johnson† • Janssen Pharmaceuticals† 	<ul style="list-style-type: none"> • DCRI‡ 	None
Mary Barton	National Committee for Quality Assurance, Vice President	None	None	None	None	<ul style="list-style-type: none"> • Kaiser (Spouse) † • National Committee for Quality Assurance† 	None
Craig Beam	Medical Development Specialists—Senior Vice President	None	None	None	None	None	None
L. Hayley Burgess	HCA Clinical Services Group—Director of Medication Safety and System Innovations	None	None	None	None	None	None
Donald E. Casey, Jr.	Atlantic Health— Chief Medical Officer	None	None	None	None	None	None
Joseph P. Drozda, Jr.	Mercy Health— Director, Outcomes Research	None	None	None	<ul style="list-style-type: none"> • FDA/Harvard University: Principal Investigator † 	<ul style="list-style-type: none"> • Boston Scientific Rhythm Management (son) † • AMA-PCPI Executive Committee * 	None
Gregg C. Fonarow	Ahmanson-UCLA Cardiomyopathy Center—Director, Division of Cardiology	<ul style="list-style-type: none"> • Amgen • Bayer • Boston Scientific • Johnson & Johnson • Medicines Company • Medtronic • Novartis† • Takeda 	None	None	<ul style="list-style-type: none"> • Gambro • Medtronic • NHLBI† • NIH/NIAID† • Novartis† • PRT* 	<ul style="list-style-type: none"> • ACC/AHA Task Force on Data Standards* • ACTION Registry GWTG Steering Committee Chair* • AHA Manuscript oversight committee* • ACC/AHA Task Force on Performance Measures * • AHA Consumer Health Quality Coordinating Committee * • IMPROVE HF 	None

						Steering Committee*	
David Goff, Jr.	Wake Forest University—Professor of Medicine	None	None	None	None	• Denver Metro AHA * • Dean, Colorado School of Public Health †	None
Kathleen L. Grady	Blumh Cardiovascular Institute—Administrative Director, Center for Heart Failure	None	None	None	• AHA † • NHLBI	• AHA*	None
P. Michael Ho	Stanford University School of Medicine—Professor of Medicine	• Wellpoint, Inc..	None	None	None	None	None
Dana King	Medical University of South Carolina—Professor & Vice Chair, Department of Family Medicine	• Pfizer/ Beohringer Ingelheim	None	None	None	None	None
Marjorie L. King	Columbia University (Helen Hayes Hospital)—Director, Cardiac Rehabilitation	None	None	None	None	None	None
Frederick A. Masoudi	University of Colorado at Denver—Associate Professor of Medicine, Division of Cardiology	None	None	None	• AHRQ † • NHLBI † • Oklahoma Foundation for Medical Quality †	• ACC † • AHA • Massachusetts Medical Society	• Plaintiff: 2012 Acute Coronary Syndrome, Expert Opinion.
David R. Nielsen	The American Academy of Otolaryngology—Chief Executive Officer & Executive Vice President	None	None	None	None	• AAO † • CMSS* • AMA-PCPI*	None
Stephen Stanko	Mended Hearts—Chair, Catherization Patient Outreach	None	None	None	None	None	None

1
2 This table represents all relationships of committee members with industry and other entities that were reported by authors, including those not deemed to be relevant to this
3 document, at the time this document was under development. A person is deemed to have a *significant* interest in a business if the interest represents ownership of 5% or more of
4 the voting stock or share of the business entity, or ownership of \$10 000 or more of the fair market value of the business entity; or if funds received by the person from the business
5 entity exceed 5% of the person’s gross income for the previous year. A relationship is considered to be *modest* if it is less than significant under the preceding definition.
6 Relationships that exist with no financial benefit are also included for the purposes of transparency. Relationships in this table are modest unless otherwise noted.

7 *No financial relationship †Significant (greater than \$10 000) relationship.

8
9
10 AAO indicate American Academy of Otolaryngology; AACVPR indicates American Association of Cardiovascular and Pulmonary Rehabilitation; AAFP, American Academy of
11 Family Physicians; ACC, American College of Cardiology; ACTION-GWTG; ACTION Get with the Guidelines; AHA, American Heart Association, AHRQ, Agency for
12 Healthcare Research and Quality; AMA-PCPI, American Medical Association—Physician Consortium for Performance Improvement; ANA, American Nurses Association;

Peterson et al.

Clinician-Patient Shared Accountability in Performance Measures

© 2014 by the American College of Cardiology Foundation and the American Heart Association, Inc.

1 ASHP, American Society of Health-System Pharmacists; CMSS, Council of Medical Specialty Societies; DCRI, Duke Clinical Research Institute; HCA, Hospital Corporation of
2 America; IMPROVE HF, Improve the Use of Evidence-Based Heart Failure Therapies in the Outpatient Setting; NHLBI, National Heart, Lung and Blood Institute; NIAID,
3 National Institute of Allergy and Infectious Diseases; NIH, National Institutes of Health; and PRT, Pharmaceutical Roundtable; UCLA, University of California, Los Angeles.
4

5 ‡DCRI has numerous grants and contracts sponsored by industry. These include the following: Aastrom Biosciences†; Abbott†; Abiomed†; Acom Cardiovascular†; Adolor
6 Corp.†; Advanced Cardiovascular Systems†; Advanced Stent Technologies†; Adynnx; Aijnomoto†; Allergan†; Amgen†; Alnylam Pharma†; Alpharma†; Amylin
7 Pharmaceuticals†; Anadyst†; Anesiva†; Angel Medical Systems†; ANGES MG†; Angiomedrix†; APT Nidus Center†; ASCA Biopharma†; Astellas Pharma†; Asklepios†;
8 AstraZeneca†; Atritech†; Attention Therapeutics†; Aventis†; Baxter†; Bayer†; Berlex†; BG Medicine†; Biogen†; Biorex Therapeutics†; Biomarker Factory†; Biosite†; Boehringer
9 Ingelheim Biogen†; Boston Scientific†; Bristol-Myers Squibb†; BMS Pfizer†; Carbomed†; CardioDx†; CardioKinetix†; Cardiovascular Systems†; Cardiovox†; Celsion Corp.†;
10 Centocor†; Cerexa†; Chase Medical†; Conatus Pharmaceuticals†; Conor Medsystems†; Cortex†; Corgentech†; CSL Behring†; CV Therapeutics†; Daiichi Pharmaceuticals†;
11 Daiichi-Sankyo†; Daiichi-Sankyo Lilly†; Datascope; Dendreon†; Dainippon†; Dr. Reddy's Laboratories; Eclipse Surgical Technologies†; Edwards Lifesciences†; Eisai†;
12 Endicor†; EnteroMedics†; Enzon Pharmaceuticals†; Eli Lilly†; Ethicon†; Ev3†; Evalve†; F2G†; Flow Cardia†; Fox Hollow Pharmaceuticals†; Fujisawa†; Genetech†; General
13 Electric†; General Electric Co.†; General Electric Healthcare†; General Electric Medical Systems†; Genzyme Corp.†; Genome Canada†; Gilead Sciences†; GlaxoSmithKline†;
14 Guidant Corp.†; HeartScape Technologies†; Hoffman-LaRoche†; Hospira†; Idera Pharmaceuticals†; Ikaria†; Imcor Pharmaceuticals†; Immunex†; INFORMD†; Inimex†; Inspire
15 Pharmaceuticals†; Ischemix†; Janssen†; Johnson and Johnson†; Jomed†; Juventus Therapeutics†; KAI Pharmaceuticals†; King Pharmaceuticals†; Kyowa Pharma†; Luitpold†;
16 Mardil†; MedImmune†; Medscape†; Medtronic Diabetes†; Medtronic†; Medtronic Vascular†; Merck Group†; MicroMed Technology†; Millennium Pharmaceuticals†; Mitsubishi
17 Tanabe†; Momenta†; Nabriva†; Neuron Pharmaceuticals†; NitroMed; NovaCardia Inc†; Novartis AG Group†; Novartis Pharmaceuticals†; Oncura†; Orexigen†; Ortho-McNeil-
18 Janssen†; OSI Eyetech†; OSI Pharmaceuticals†; Pfizer†; Pharmacyclics†; Pharmasset†; Pharmsos†; Phyxius Pharmaceuticals; Pharsight†; Pluristen Therapeutics†; Portola
19 Pharmaceuticals†; Proventys†; Radiant†; Regado Biosciences†; Rengeneron Pharmaceuticals†; Roche Molecular Systems†; Roche Group†; Roche Diagnostic†; Salix
20 Pharmaceuticals†; Sanofi-Pasteur, Inc; Sanofi-aventis†; Santaris Pharmaceuticals†; Schering-Plough†; Scios†; Siemens†; Southwest Oncology Group†; Spectranetics†; Summit†;
21 Sunovion Pharmaceuticals†; TAP Pharmaceutical Products†; Tengion†; The Medicines Company†; Theravance†; TherOx†; Tethys Bioscience†; Theregen†; Three Rivers
22 Pharmaceuticals†; The EMMES Corporation†; UCB†; Valentis†; Valleylab†; Vertex†; Viacor† and Wyeth†.

23

Appendix B: Comprehensive Reviewer Relationships With Industry and other entities – ACC/AHA/AACVPR/AAFP/ANA The Concepts for Clinician–Patient Shared Accountability in Performance Measures

Peer Reviewer	Representation	Consultant	Speaker	Ownership/ Partnership/ Principal	Research	Institutional, Organizational or Other Financial Benefit	Expert Witness
Mazen Abu-Fadel	Content Reviewer- ACC Councils and Sections	None	• Abbott Vascular	None	None	None	None
Cynthia Arslanian-Engoren	Content Reviewer- AHA Committee: CV and Stroke Nursing Council	None	None	None	None	None	None
Brian Carlin	Official Reviewer- AACVPR	•Glaxo Smith Kline, Respiroics, Forest, Breathe Technologies, Boehringer-Ingelheim †	None	None	None	• National Board for Respiratory Care* • National Lung Health Education Program*	None
Lola Coke	Official Reviewer- ANA	None	None	None	None	None	None
Eileen Collins	Official Reviewer- AACVPR	None	None	None	None	None	None
Silvana Lawrence	Content Reviewer- ACC Councils and Sections	None	None	None	None	None	None
Maulik D. Majmudar,	Content reviewer- ACC Patient-Centered Care Committee	None	None	None	None	None	None
Ariane Marelli	Content Reviewer- ACC Councils and Sections	None	None	None	None	None	None
Robert Piana	Content Reviewer- ACC Councils and Sections	•W.L. Gore & Associates, Inc. •HCRI •Axio Research	None	None	• Amplatzer Corporation	• Vasutek	• 2012: Third Party Quality Review • 2012: Defendant-Interventional Cardiology • 2011: Defendant CAD Management • 2011 Defendant: Interventional

Peterson et al.

Clinician-Patient Shared Accountability in Performance Measures

© 2014 by the American College of Cardiology Foundation and the American Heart Association, Inc.

Peer Reviewer	Representation	Consultant	Speaker	Ownership/ Partnership/ Principal	Research	Institutional, Organizational or Other Financial Benefit	Expert Witness
							Cardiology
Sara Paul	Content Reviewer- AHA Committee: CV and Stroke Nursing Council	None	None	None	None	• Heart Failure Society of America*	None
Susan Pressler	Content Reviewer- AHA Committee: CV and Stroke Nursing Council	None	None	None	None	• Pfizer* • NIH †	None
Michael Rich	Content Reviewer- ACC Councils and Sections	None	None	None	None	None	None
Barbara Riegel	Official Reviewer- AHA	None	None	None	None	• NIH • AHA*	None
William Roach	Official Reviewer- AHA	None	None	None	None	• AHA*	None
Darryl Roberts	Official Reviewer- ANA	None	None	None	None	None	None
Joachim Roski	Official Reviewer- AMA-PCPI	None	None	None	None	None	None
Amy Schneider	Official Reviewer- AAFP	None	None	None	None	None	None
Chittur Sivaram	Content Reviewer- ACC Councils and Sections	• Medtronic	None	None	None	None	None
Karen Walker	Content Reviewer- ACC Councils and Sections	None	None	None	None	None	None
Minnow Walsh	Content Reviewer- ACC CQC Committee and ACC Patient-Centered Care Committee	• Eli Lilly • Novartis • United HealthCare	None	None	None	None	None

This table represents the relevant relationships with industry and other entities that were disclosed at the time of peer review. It does not necessarily reflect relationships with industry at the time of publication. A person is deemed to have a significant interest in a business if the interest represents ownership of 5% or more of the voting stock or share of the business entity, or ownership of \$10 000 or more of the fair market value of the business entity, or if funds received by the person from the business entity exceed 5% of the person's gross income for the previous year. A relationship is considered to be modest if it is less than significant under the preceding definition. Relationships that exist with no financial benefit are also included for the purposes of transparency. Relationships in this table are modest unless otherwise noted.

Peterson et al.

Clinician-Patient Shared Accountability in Performance Measures

© 2014 by the American College of Cardiology Foundation and the American Heart Association, Inc.

AACVPR indicates American Association of Cardiovascular and Pulmonary Rehabilitation; AAFP, American Academy of Family Physicians; ACC, American College of Cardiology; AHA, American Heart Association; AMA-PCPI, American Medical Association–Physician Consortium for Performance Improvement; ANA, American Nurses Association; ASHP, American Society of Health-System Pharmacists; CQC: Clinical Quality Committee; NCQA, National Committee for Quality Assurance; NIH, National Institute of Health.